Lichtenstein M - Search Results

1

Lichtenstein M, Zimran A, Horowitz M. Lichtenstein M, et al. Blood Cells Mol Dis. 1997 Dec;23(3):395-401. doi: 10.1006/bcmd.1997.0156. Blood Cells Mol Dis. 1997. PMID: 9446753

2

Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease.

Shteingart S, Rapoport M, Grodzovski I, Sabag O, Lichtenstein M, Eavri R, Lorberboum-Galski H. Shteingart S, et al. Among authors: lichtenstein m. Gut. 2009 Jun;58(6):790-8. doi: 10.1136/gut.2008.153981. Epub 2008 Oct 31. Gut. 2009. PMID: 18978179

3

The Beneficial Effect of Mitochondrial Transfer Therapy in 5XFAD Mice via Liver-Serum-Brain Response.

Sweetat S, Nitzan K, Suissa N, Haimovich Y, Lichtenstein M, Zabit S, Benhamron S, Akarieh K, Mishra K, Barasch D, Saada A, Ziv T, Kakhlon O, Lorberboum-Galski H, Rosenmann H. Sweetat S, et al. Among authors: lichtenstein m. Cells. 2023 Mar 24;12(7):1006. doi: 10.3390/cells12071006. Cells. 2023. PMID: 37048079 Free PMC article.

4

Systematic Approaches to Study Eclipsed Targeting of Proteins Uncover a New Family of Mitochondrial Proteins.

Mark M, Klein O, Zhang Y, Das K, Elbaz A, Hazan RN, Lichtenstein M, Lehming N, Schuldiner M, Pines O. Mark M, et al. Among authors: lichtenstein m. Cells. 2023 Jun 5;12(11):1550. doi: 10.3390/cells12111550. Cells. 2023. PMID: 37296670 Free PMC article.

5

Utilizing a GnRH-based chimeric protein for the detection of adenocarcinoma.

Lichtenstein M, Ben-Yehudah A, Belostotsky R, Eaveri R, Sabag O, Grodzovski I, Lorberboum-Galski H. Lichtenstein M, et al. Int J Oncol. 2005 Jul;27(1):143-8. Int J Oncol. 2005. PMID: 15942653

6

IL2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitis.

Irony-Tur-Sinai M, Lichtenstein M, Brenner T, Lorberboum-Galski H. Irony-Tur-Sinai M, et al. Among authors: lichtenstein m. Int Immunopharmacol. 2009 Sep;9(10):1236-43. doi: 10.1016/j.intimp.2009.07.006. Epub 2009 Jul 22. Int Immunopharmacol. 2009. PMID: 19631295

7

IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathway.

Grodzovski I, Lichtenstein M, Galski H, Lorberboum-Galski H. Grodzovski I, et al. Among authors: lichtenstein m. Int J Cancer. 2011 Apr 15;128(8):1966-80. doi: 10.1002/ijc.25527. Int J Cancer. 2011. PMID: 20568105

8

α-Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson's disease.

Israeli E, Yakunin E, Zarbiv Y, Hacohen-Solovich A, Kisos H, Loeb V, Lichtenstein M, Ben-Gedalya T, Sabag O, Pikarsky E, Lorberboum-Galski H, Sharon R. Israeli E, et al. Among authors: lichtenstein m. PLoS One. 2011;6(5):e19622. doi: 10.1371/journal.pone.0019622. Epub 2011 May 18. PLoS One. 2011. PMID: 21611169 Free PMC article.

9

Eliminating the six N-terminal amino acids of the caspase 3 large subunit improved production of a biologically active IL2-Caspase3 chimeric protein.

Glantz Y, Sabag O, Lichtenstein M, Grodzovski I, Lorberboum-Galski H. Glantz Y, et al. Among authors: lichtenstein m. Biotechnol Prog. 2012 Mar-Apr;28(2):573-80. doi: 10.1002/btpr.1515. Epub 2012 Mar 5. Biotechnol Prog. 2012. PMID: 22275241

10

Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells.

Marcus D, Lichtenstein M, Saada A, Lorberboum-Galski H. Marcus D, et al. Among authors: lichtenstein m. Mol Med. 2013 Jul 24;19(1):124-34. doi: 10.2119/molmed.2012.00343. Mol Med. 2013. PMID: 23670274 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

412 results

Search Page

Filters